Introduction {#S1}
============

Neural population activity in the cerebral cortex fluctuates continuously, even in the absence of changes in sensory input or motor output. These so-called intrinsic cortical activity fluctuations show remarkable structure across time and space: activity fluctuations correlate across sets of distributed brain areas, on the basis of which macroscale functional networks can be delineated ([@B20]; [@B56]). Such intrinsic activity correlations are commonly studied in a setting that is often referred to as the "resting state": the absence of motor output or structured sensory input (often with eyes-closed). However, intrinsic activity fluctuations that correlate across time and space also occur during active processing of sustained, unchanging, sensory input ([@B49]; [@B112]; [@B128]). We therefore use the term "intrinsic activity correlations," as it is agnostic about the behavioral context.

We focus on intrinsic correlations between cortical population signals that pool the activity across thousands of individual neurons. Intrinsic activity fluctuations have also been investigated at the level of single-neuron spiking, in this context commonly referred to as "noise correlations" ([@B194]; [@B35]; [@B125]; [@B92]). Similar to the intrinsic correlations between cortical population signals reviewed below, noise correlations between single neurons are state-dependent (e.g., [@B72]; [@B136]; [@B83]). An important open question, beyond the scope of this review, is whether or not the same mechanistic principles account for the impact of state variations on neural correlations at these different (microscopic vs. macroscopic) scales. In this article, we use the term "intrinsic (cortical activity) correlations" to exclusively refer to correlations between cortical population signals.

Although predominantly studied with functional magnetic resonance imaging (fMRI), intrinsic correlations have also been shown to occur using electro-/magnetoencephalography (E/MEG), electrocorticography, and other imaging modalities ([@B59]; [@B104]; [@B126]; [@B41]; [@B77]; [@B95]; [@B157]; [@B161]; [@B78]) and show spatiotemporal correspondence across modalities ([@B76]; [@B157]). The temporal structure of intrinsic activity varies across cortical areas, which may reflect inter-areal variation in computational properties such as intrinsic timescales ([@B121]) that depend on inter-areal projections ([@B33]) and, possibly, functional interactions ([@B10]). Moreover, intrinsic activity correlations are largely predictive of task-related activation patterns ([@B37]; [@B166]), and provide useful diagnostic and prognostic markers of neurological and psychiatric disorders ([@B57]; [@B175]). Thus, intrinsic activity correlations are a ubiquitous phenomenon and their quantitative features ([Box 1](#BX1){ref-type="boxed-text"}) are potentially revealing indicators of the functional architecture of the brain.

###### Box 1. Quantifying features of intrinsic activity correlations.

In this article, we discuss three characteristics of intrinsic activity correlations:

1.  The *strength/magnitude* of correlations in activity. Correlation strength can be used to examine the extent to which activity between any two brain regions is correlated (so-called seed-based correlation analysis), or to examine the overall "connectedness" of the brain by averaging the correlation coefficient across all brain region or deriving summary statistics such as "degree" ([@B140]) or "functional connectivity density" ([@B168]).

2.  *Topography:* A spatial representation of (some property of) a system. For example, the spatial distribution of a particular resting state network (RSN), defined as a set of brain regions or voxels that shows consistent spatio-temporal dynamics (usually above a particular threshold). The topography is often used to characterize the structure of individual RSNs, or experimental manipulation-related changes therein ([@B158]).

3.  *Topology*: The geometrical relationship between elements of a system. The human brain has been argued to approximate a *small world* topology, which forms a mixture of dense connections between neighboring brain regions and sparse long-range connections ([@B183]; [@B159]; [@B13]; [@B14]). Such a topology allows for both distributed and integrated processing, the balance between which relates to task-performance ([@B156]; [@B153]).

A number of observations indicate that the features of intrinsic activity correlations are shaped by the architecture of anatomical connections of the cerebral cortex. First, intrinsic correlations within the visual system reflect established principles of cortico-cortical projections, such as retinotopic organization ([@B74]; [@B49]; [@B67]; [@B21]). Second, computational models that are equipped with realistic anatomical connectivity can predict the topological features and temporal dynamics of empirical intrinsic correlations reasonably well ([@B79], [@B80]; [@B26]). Third, causal manipulation of anatomical connections alters the strength of functional interactions ([@B127]). This line of inquiry thus suggests that the full repertoire of functional interactions across the brain is shaped by the anatomical substrate upon which these interactions unfold ([@B42]).

However, other observations indicate that the anatomical connectome alone is not *sufficient* to account for the features of intrinsic activity correlations. The correspondence between the anatomical and functional connectome varies with attentional ([@B10]) and conscious ([@B12]) state, and shows substantial temporal variability even within periods of rest ([@B32]; [@B142]; [@B5]; [@B190]; [@B102]). What are the sources of these variations of intrinsic activity correlations?

Here, we focus on one candidate source that has received surprisingly little attention in the resting-state literature, but, as we propose, is crucial for understanding the origin, dynamics, and diagnostic value of intrinsic activity correlation: the neuromodulatory systems of the brainstem. The term refers to a small set of brainstem nuclei with widespread projections to the forebrain, which synthesize and release specific modulatory neurotransmitters ("neuromodulators"; [Figure 1](#F1){ref-type="fig"} and [Box 2](#BX2){ref-type="boxed-text"}). By virtue of their widespread projection profiles and effects on the state of cortical target networks, these systems can shape neural activity across the cortex in a coordinated fashion. Consequently, these systems are in an ideal position to shape intrinsic activity correlations. What is more, these brainstem systems are disturbed in several major psychiatric disorders, which also coincide with changes in intrinsic activity correlations ([@B27]; [@B139]; [@B181]; [@B179]; [@B8]; [@B47]; [@B118]; [@B65]).

![Schematic of major neuromodulatory systems. Cerebellar, spinal, and temporal projections are omitted for brevity. The inset shows the approximate anatomical location of each nucleus that sends major afferents to the forebrain.](fnhum-13-00340-g001){#F1}

###### Box 2. Major brainstem neuromodulatory systems.

Besides various peptides, five major neuromodulatory systems have been identified:

1.  *Norepinephrine* (NE) is released by the locus coeruleus (LC), and the A1/A2 regions of the brainstem ([@B144]). The LC projects to virtually all areas of the forebrain with the exception of the basal ganglia. Projection specificity of sub-populations of LC neurons has recently been shown ([@B30]; [@B31]; [@B146]; [@B147]; [@B171], [@B172]; [@B137]; [@B29]).

2.  *Dopamine* (DA) is predominantly released by two nuclei: the substantia nigra pars compacta (SNpc) and the ventral tegmental area (VTA) ([@B54]). Four major dopaminergic branches exist of which three are ascending: the mesolimbic (VTA to ventral striatum), mesocortical (VTA to cortex) and nigrostriatal (SNpc to dorsal striatum) pathways. In addition, DA co-release by the LC ([@B164]; [@B15]) and serotonergic dorsal raphe nuclei ([@B34]) have recently been shown. Other DA-producing neurons are found in the olfactory bulb ([@B130]) and pedunculopontine nucleus ([@B58]). DA and NE have a similar chemical composition and are collectively known as catecholamines.

3.  *Acetylcholine* (ACh) is released by neurons in the basal forebrain (BF), which is comprised of several subdivisions, termed Ch1-Ch4, that contain cholinergic neurons. Ch4 corresponds to the nucleus basalis of Meynert, and is the major source of cortical ACh ([@B113]; [@B115]; [@B114]). This nucleus contains topographically organized clusters of neurons that preferentially innervate select portions of the cortex ([@B137]; [@B188]; [@B2]). Other sources of ACh include the pedunculopontine nucleus and laterodorsal tegmental nucleus of the brainstem, which project to the thalamus, basal ganglia, hypothalums, and cortex ([@B160]; [@B62]; [@B58]).

4.  *Serotonin* (5HT) originates from the raphe nuclei, which is a constellation of nuclei scattered throughout the brainstem ([@B169]). The raphe nuclei can be roughly subdivided in rostral and caudal portions, of which the rostral portion can be further subdivided in a dorsal (B6-B7) and median (B5/B8) portion. Both the dorsal rand median raphe project heavily to the cortex ([@B169]).

5.  *Histamine* is released by the tuberomammilary nucleus of the hypothalamus that projects to virtually the entire forebrain ([@B71]).

Most neuromodulatory brainstem nuclei do not consist of a single type of neuron releasing one neuromodulator, but contain a mixture of multiple types of neurons that can include GABAergic or glutamatergic types as well as other neuromodulators ([@B97]; [@B34]; [@B15]; [@B23]). Furthermore, some of these nuclei are reciprocally connected and their activity tends to co-fluctuate in unison with changes in arousal and wakefulness ([@B54]; [@B71]; [@B144]).

In what follows, we review the dependence of intrinsic activity correlations on neuromodulatory systems. An increasing number of studies over the past decade, conducted in humans, macaques, and rodents (rats and mice), have begun to provide insight into this dependence. Our goal is to provide a structured overview of this nascent literature and distil from it a number of emerging principles. This article is a selective review, which focuses on emerging principles rather than a comprehensive coverage of the literature. Moreover, we focus on the neuromodulatory systems on which most work has been conducted. In particular, the catecholaminergic systems (norepinephrine, NE; and dopamine, DA) were among the first systems to be studied in relation to intrinsic activity correlations. This article also covers more recent work into the acetylcholine (ACh) and serotonin (5HT) systems. To date, comparatively little work has been conducted on the system-level effects of histamine, and it will therefore not be discussed in the current review.

Candidate Mechanisms of Brainstem Modulation of Intrinsic Cortical Activity Correlations {#S2}
========================================================================================

The distinction between two modes of cortical state provides a useful heuristic for conceptualizing potential effects of brainstem neuromodulatory systems on cortical network dynamics: "*activity state*" and "*dynamic state*" ([@B39]; [@B141]). This (likely oversimplified) dichotomy can be formalized by means of dynamical systems models. [@B39] and [@B141] used the FitzHugh--Nagumo model \[originally developed for describing action potential generation ([@B52]; [@B122])\] for modeling cortical population dynamics ([@B39]; [@B141]). In this framework, *activity state* refers to the set of parameters that vary on timescales from milliseconds to hundreds of milliseconds, and *dynamic state* refers to the set of parameters that vary more slowly (from seconds to tens of seconds) and *interact multiplicatively with* (i.e., modulate) the fast variations of activity states ([@B39]; [@B101]; [@B72]; [@B141]).

In physiological terms, activity state can be conceptualized as common measures of "neuronal activity": membrane potential or spiking activity. Changes in these measures of neuronal activity are caused by excitatory or inhibitory postsynaptic potentials, mediated by point-by-point synaptic transmission via ionotropic receptors (predominantly for glutamate and GABA). This form of synaptic transmission is the means of intracortical interactions and lies at the heart of current large-scale computational models of intrinsic activity correlations ([@B79], [@B80]; [@B22]; [@B43], [@B44]).

By contrast, variations in dynamic state can be conceptualized as the slower effects of neuromodulators, mediated by "volume transmission" (i.e., not point-by-point synapses) and by metabotropic receptors that do not alter the postsynaptic membrane potential directly. Activation of metabotropic receptors sets in motion intracellular signaling cascades that alter the way in which neurons respond to input over protracted periods of time, from changing the conductance of ionotropic receptors to altering the expression of genes. For example, catecholamines (in particular noradrenaline) change the balance between excitation and inhibition in the local microcircuit ([@B60]; [@B106]; [@B128]). This circuit effects in turn increases the responsivity of cortical neurons to synaptic input ([@B117]; [@B138]; [@B149], [@B148]; [@B180]), an effect referred to as "neural gain": an increase in the slope of the input-output function ([@B19]; [@B119]; [@B185]; [@B48]; [@B132]). This mechanism of action corresponds to the common notion of "neuromodulation."

Importantly, while the majority of receptors for neuromodulators are metabotropic, some of them are ionotropic -- in particular, the nicotinic class of ACh receptors ([@B82]), and the 5HT~3~ subclass of serotonin receptors ([@B11]). Activation of both receptor types leads to rapid activation of cortical networks ([@B134]; [@B61]; [@B110]; [@B184]; [@B111]). Moreover, changes in the activity of neuromodulatory nuclei coincide with ([@B51]), and cause ([@B131]) rapid fluctuations in activity state (e.g., the transition from the "down" to "up" state of synchronized cortical population activity). Serotonergic or cholinergic activation of ionotropic receptors thus constitutes a mechanism by which neuromodulatory brainstem system can rapidly change the cortical activity state.

In sum, neuromodulators may, in principle, alter intrinsic activity correlations in two ways. First, by rapidly changing the activity state of distributed sets of cortical regions through common (excitatory or inhibitory) drive ([@B50]). Second, neuromodulators may change the dynamic state (e.g., excitation--inhibition balance) of sets of cortical regions in a coordinated fashion but on slower timescales. Such coordinated changes in dynamic state, in turn, may directly produce correlations between population activity, but they can also modulate the correlations produced by cortical interactions through altering local dynamics ([@B44]; [@B128]). The two principal mechanisms (modulation of activity state vs. dynamic state) reflect the distinct effects of cortical (ionotropic vs. metabotropic) receptors. Importantly, both mechanisms can produce intrinsic activity correlations ([@B94]), even in the absence of any effect on cortico--cortical interactions.

While the projections of neuromodulatory nuclei to the cortex are commonly known as widespread or diffuse, there is substantial heterogeneity and specificity in these projections, part of which is only now being uncovered through novel anatomical tracing techniques ([@B54]; [@B30]; [@B31]; [@B146]; [@B147]; [@B171], [@B172]; [@B85]; [@B23]). What is more, the cortical distributions of the various different receptors for each neuromodulator are heterogeneous ([@B135]; [@B193]; [@B123]; [@B143]), which is evident for the human cortex in recent maps of receptor gene expression ([Figure 2](#F2){ref-type="fig"}). Consequently, input from any neuromodulatory nucleus to the cortex, changing activity state, dynamic state, or both, might translate into spatially structured correlations of neural population signals in the cortex. For this reason, it is critical to consider the potential impact of neuromodulatory brainstem systems when making inferences about physiological cortico--cortical interactions (and "cortical networks") from the correlation of intrinsic cortical activity alone.

![Overview of cortical distributions of genetic expression of neuromodulator receptors in the human brain. Receptor maps were taken from [@B68], projected onto the cortical surface, and Z-scored across space. Files and tool for plotting these maps can be found here: [github.com/rudyvdbrink/receptormaps](https://github.com/rudyvdbrink/receptormaps). Abbreviations: D: dopamine; ACh: acetylcholine; M: muscarinic; N: nicotinic; 5HT: serotonin; H: histamine.](fnhum-13-00340-g002){#F2}

Correlated Cortical Activity Driven by Intrinsic Fluctuations of Brainstem Activity {#S3}
===================================================================================

If neuromodulatory nuclei rapidly drive cortical activity in widespread target networks via ionotropic mechanisms then (i) removing neuromodulatory drive on the cortex should attenuate correlated activity within the cortex, and (ii) manipulating the time-varying activity of neuromodulatory nuclei should similarly affect the time-varying activity within the cortex, and (iii) activity within neuromodulatory nuclei should co-vary with intrinsic activity in large areas of the cortex. These predictions also hold if neuromodulatory nuclei potentiate drive from other sources such as the thalamus.

Causal Manipulation of Time-Varying Neuromodulatory Activity {#S3.SS1}
------------------------------------------------------------

Evidence for the first two predictions comes from studies in which the time varying activity of neuromodulatory nuclei is manipulated. [@B170] reversibly inactivated portions of the BF using the GABA~A~ agonist muscimol in rhesus macaques, thus removing potential fluctuating common input to cortical areas. This manipulation reduced correlations between the "global" BOLD-fMRI signal (i.e., the average across all gray matter voxels) and voxel-wise activity topographically aligned with the afferents of the inactivated BF location. Because the BF sends GABAergic as well as cholinergic projections to the cortex, these findings do not necessarily reflect cholinergic effects. [@B66] rhythmically stimulated serotonergic neurons in the DR with optogenetics in rodents, and measured the cerebral blood volume (CBV) response with fMRI (CBV was used because of putative signal-to-noise advantages over BOLD-fMRI). Cortical CBV showed widespread, correlated troughs in amplitude in response to DR stimulation. Moreover, the cortical distribution of CBV responses correlated spatially with reductions in burst rate and delta-band power as measured electrophysiologically.

Combined, these two studies ([@B170]; [@B66]) provide the strongest evidence to date of a mediation of (a part of) intrinsic activity correlations through rapid, common input from neuromodulatory brainstem nuclei that are consistent with correlated changes in activity state. A critical test of this notion would, however, use as a neural marker of interest correlations between spiking activity in different cortical regions, rather than between their BOLD or CBV signals. This is because changes in the latter signals may not necessarily reflect changes in cortical activity state (i.e., spiking activity; [@B103]) but may be produced by changes in dynamic state ([@B99]).

Analogous evidence for the LC-NE system comes from older positron emission tomography (PET) work by [@B38] who reduced LC-activity via clonidine ([@B53]) in healthy humans. During rest, clonidine caused broad reductions in directed coupling of PET activity between several cortical and sub-cortical regions. Due to the sluggish nature of the PET signals measured, however, it is difficult to attribute these results to changes in activity or dynamic state. In addition, DA depletion has similarly been reported to cause broad reductions in fMRI activity correlation strength ([@B152]).

Temporal Co-variation Between the Brainstem and the Cortex {#S3.SS2}
----------------------------------------------------------

The prediction that activity in neuromodulatory nuclei should co-vary with cortical activity can be tested using seed-based correlation analyses, where (fMRI) activity in neuromodulatory nuclei is correlated with cortical activity. A limited number of such studies have been conducted. Because of the small size and spatial proximity of these nuclei to the ventricles ([Figure 1](#F1){ref-type="fig"}) and strong effects of physiological noise, these types of measurements require non-standard approaches to fMRI measurement and data analysis ([@B7]; [@B90]; [@B24]; [@B17]; [@B40]; [@B55]). Therefore, unless mentioned otherwise, we only considered studies where retrospective image correction for physiological noise was applied.

[@B192] assessed correlations between the cortex and LC, VTA, and SN, as defined by anatomical atlases ([@B3]; [@B87]). They reported widespread negative correlations between the cortex and all three brainstem nuclei and predominantly positive correlations between activity in these nuclei and other subcortical areas. [@B98] found that peaks in the global (gray matter voxel averaged) signal coincided with troughs in activity of the BF, suggesting an anti-correlation between BF activity and cortical activity. This is in line with earlier findings by [@B96], who reported widespread negative correlation between BF and cortical areas, although no correction for physiological noise was applied in this study. By contrast, [@B105] found positive correlations between anatomically defined BF subdivisions ([@B187]) and known cortical targets of BF projections, possibly due to the fact that in this study partial correlation was used to examine subdivision-specific correlations. Lastly, [@B18] found relatively confined partial correlations between the cortex and anatomically and \[^11^C\]DASB PET-binding constrained delineations of the dorsal and median raphe nuclei.

Summary and Outstanding Issues {#S3.SS3}
------------------------------

The most direct evidence for intrinsic activity correlations through common drive of distributed cortical regions by neuromodulatory systems comes from direct manipulations of the activity of the corresponding brainstem nuclei. However, such studies are sparse and have not yet been conducted for all neuromodulatory nuclei. In addition, activity in most, but not all, neuromodulatory nuclei has been reported to covary with widespread areas of the cortex. However, to the best of our knowledge, no study to date has examined the individual contribution of the full set of neuromodulatory nuclei ([Figure 1](#F1){ref-type="fig"} and [Box 2](#BX2){ref-type="boxed-text"}) to intrinsic activity fluctuations within the cortex. This leaves open the possibility that any correlation between an individual nucleus and the cortex is due to shared fluctuations across neuromodulatory nuclei ([@B40]) rather than reflecting specific drive of one neuromodulatory nucleus on cortical activity. Moreover, removal of the global signal (as done by e.g., [@B18]) may obscure wide-spread correlations and reveal only those correlations that are stronger than global components of the cortical signal (i.e., the mean of all cortical regions). Another important limitation of all studies assessing intrinsic activity correlations by means of the fMRI signal, is that that the latter may reflect either changes in activity state (spike rate) or changes in dynamic state produced by neuromodulatory mechanisms ([@B99]).

In sum, the available studies are consistent with the notion of common drive of distributed cortical regions by the fluctuating activity of neuromodulatory nuclei. In this light, at least part of the spatial structure of intrinsic activity correlations within the cortex may reflect the spatial distribution of the projections of these brainstem nuclei, or their receptors, rather than the topography of cortico-cortical connections. Further experiments and direct comparisons of the contribution of individual neuromodulatory nuclei on intrinsic activity correlations are warranted, bearing in mind the above-mentioned interpretational caveats.

Changes in Intrinsic Cortical Correlations Under Pharmacological Intervention {#S4}
=============================================================================

A major approach in the study of neuromodulatory systems is to manipulate neuromodulator levels via pharmacological intervention, and measure the resulting effects on cortical activity. Such pharmacological intervention will primarily exert its effects on cortical activity through sustained alterations of cortical circuit properties (i.e., shifts in cortical dynamic state), and less (or not at all) by altering the rapid drive of cortical regions, although it has been shown that the NE-reuptake inhibitor atomoxetine alters the dynamics of LC activity (e.g., via auto-receptors) ([@B9]). For simplicity, we here heuristically treat pharmacological intervention as manipulations of changes in cortical dynamic state, and review the effects of these manipulations on intrinsic activity correlations.

We examine three key characteristics of these correlations ([Box 1](#BX1){ref-type="boxed-text"}) in order to delineate commonalities or inconsistencies across findings. First, given the widespread projection profile of neuromodulatory systems ([Figure 1](#F1){ref-type="fig"} and [Box 2](#BX2){ref-type="boxed-text"}), pharmacological manipulation of these systems may be expected to result in changes in correlation strength that encompass large areas of the cortex. We thus discuss literature that has examined such global changes of correlation strength (i.e., whole-brain increases or decreases). Second, the spatial heterogeneity of neuromodulatory projections and receptors ([Figure 2](#F2){ref-type="fig"}) across the cortex suggests that neuromodulatory systems may not only change the global strength of intrinsic activity correlations, but also result in spatially inhomogeneous changes of correlation strength ([@B174]). Third, computational modeling work indicates that modifications of circuit properties that are subject to neuromodulatory influence such as gain or excitation--inhibition balance ([@B151]; [@B132]; [@B60]; [@B128]) can alter the geometric properties of whole-brain intrinsic activity correlations (topology), even without any heterogeneity of neuromodulatory influences ([@B44]; [@B154]). We therefore discuss literature that has examined the effect of pharmacological manipulation of neuromodulator systems on RSN topography and whole-brain functional topology.

Changes of the Global Strength of Intrinsic Correlations {#S4.SS1}
--------------------------------------------------------

Several studies have examined the effect of the NE reuptake inhibitor atomoxetine, which increases cortical catecholamine levels ([@B25]; [@B46]; [@B162]; [@B91]), on global correlation strength. Using atomoxetine, [@B176] found reductions compared to placebo in graph-theoretic metrics of the global strength of intrinsic fMRI activity correlations in humans. Similarly, [@B70] found reduced atomoxetine-induced fMRI correlation strength within and between various RSNs in rhesus macaques, with an overall net change of reduced correlation. This was also reflected in a reduction in the average brain-wide weighted correlation coefficient ([@B69]). By contrast, [@B129] found no significant atomoxetine-induced change in graph theoretic metrics of activity correlations measured with MEG during rest. However, during viewing of a perceptually ambiguous visual stimulus task, [@B129] found that atomoxetine *increased* the strength of correlations. A global increase in fMRI correlations following chemogenetic LC stimulation in anesthetized mice has also been reported ([@B191]).

The above mentioned MEG-study by [@B129] also investigated the effect of increased cortical ACh levels on correlated activity. This study used the acetylcholinesterase inhibitor donepezil and found reduced correlation strength during rest, and no effect during the presentation of an ambiguous visual stimulus. Three studies have examined the effect of pharmacological modulation of the 5HT system on the global strength of fMRI correlations. [@B145] reported widespread reductions in correlation strength (quantified as the graph theoretic metric degree) following administration of the 5HT reuptake inhibitor escitalopram. Similarly, [@B133] found a widespread shift of cortical intrinsic activity correlations toward zero due to the 5HT~2A~ receptor agonist LSD -- an effect that did not occur when simultaneously administering the 5HT~2A~ antagonist ketanserin. By contrast, [@B163] reported an LSD-induced increase in the overall strength of correlations within the cortex.

Topographically Specific Changes of Intrinsic Correlation Strength {#S4.SS2}
------------------------------------------------------------------

Topographical effects of pharmacological manipulation may be informative about which sets of cortical regions ("networks") are particularly susceptible to neuromodulatory influence through a modulation of the dynamic state. Below, we provide a summary of consistent findings in the literature (see also [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). We review studies that either used whole-brain "dual regression," or correlation between a seed and the entire cortex. The term dual regression refers to sequential spatial and temporal regression of independent components with the purpose of identifying consistent spatiotemporal networks and manipulation-related changes therein ([@B16]).

###### 

Summary of main findings of (pharmacological) manipulation of catecholamines (NE and DA).

  **Study**   **Modality(species)**   **Analysismethod**                                    **Manipulation**                                      **Main effects of manipulation on intrinsic correlations**
  ----------- ----------------------- ----------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B38]      PET (humans)            Dynamic causal modeling                               Clonidine (α2 agonist)                                Rest: reduced effective connectivity from PFC to thalamus, and to and from visual cortex. Attentional task: general increase in effective connectivity, with changes centered on parietal cortex.
  [@B1]       fMRI (humans)           Graph theoretic analysis                              Sulpride (D~2~ antagonist)                            Reduced metrics of global and local efficiency.
  [@B86]      fMRI (humans)           Seed-based correlation                                L-DOPA (DA precursor)                                 Increased correlation between putamen and cerebellum and brainstem. Increased correlation between ventral striatum and vlPFC. Reduced correlation between DMN, and ventral striatum and caudate.
  [@B108]     fMRI (humans)           Seed-based correlation                                Reboxetine (SNRI)                                     Reboxetine: reduced amygdala-OFC correlation, and reduced striatal--OFC correlation.
  [@B36]      fMRI (humans)           Dual regression                                       Haloperidol (D~2~ antagonist) L-DOPA (DA precursor)   Linear increase (haloperidol \< placebo \< L-DOPA) between BG network and sensorimotor cortex. Inerted-U between BG network and dorsal anterior-mid cingulate (placebo \> haloperidol and L-DOPA). Linear decrease (haloperidol \> placebo \> L-DOPA) between DMN and sensorimotor cortex. Linear increase (haloperidol \< placebo \< L-DOPA) between DMN and SMG.
  [@B4]       fMRI (humans)           Dual regression Seed-based correlation                Dexmedetomidine (α2 agonist)                          Reduced correlation between DMN and bilateral thalamus and left cerebellum; increased correlation between DMN and IFG, putamen, and insula. Reduced correlation between rlFPN and cerebellum; increased correlation between rlFPN and cerebellum, precuneus, parietal operculum insula fusiform and angular gyri. Reduced correlation between llFPN and cerebellum, calcarine cortex, MFG, and SFG.
  [@B116]     fMRI (humans)           Seed-based correlation                                Reboxetine (SNRI) Amisulpride (D~2/3~ antagonist)     Reboxetine: increased correlation between brainstem, and thalamus and PCC; and thalamus and accumbens; reduced correlation between putamen-brainstem; amygdala-ACC; and between the accumens and two regions of the ACC; reduced correlation between accumbens and two regions in ACC. Amisulpride: increased correlation between: PCC-brainstem; amygdala, brainstem and thalamus; putamen-brainstem.
  [@B176]     fMRI (humans)           Graph theoretic analysis Seed-based correlation       Atomoxetine (SNRI)                                    Reduced metrics of global correlation strength and clustering. Reduced correlation between FPN, and DMN and visual network, and reduced correlation between the visual and sensorimotor network. Reduced correlation within a set of occipital regions. Reduced correlation between early visual cortex and the rest of the brain.
  [@B69]      fMRI (rhesus macaque)   Dual regression                                       Atomoxetine (SNRI)                                    Reduced correlation within FPN, somatosensory, sensorimotor, visual, and superior temporal sulcus networks. Reduced correlation between various networks with an overall net change of reduced correlation.
  [@B70]      fMRI (rhesus macaque)   Graph-theoretic analysis                              Atomoxetine (SNRI)                                    Reduced global efficiency. Reduced global correlation strength. Increased clustering.
  [@B186]     fMRI (humans)           Graph theoretic analysis and seed-based correlation   Pramipexole (D~2~ agonist)                            Reduced correlation between caudate and nodes of the sensorimotor network. No change in topological metrics.
  [@B155]     fMRI (humans)           Graph theoretic analysis                              Atomoxetine (SNRI)                                    Rest: reduced metrics of integration. N-back task: increased metrics of integration.
  [@B174]     fMRI (humans)           Generalized eigenvalue decomposition                  Atomoxetine (SNRI)                                    Increased correlations in a network that loosely resembled a rlFPN, and distribution of β (negatively) and D~2~ receptors. Reduced correlations in a network that loosely resembled a llFPN, sensorimotor and DMN networks, and distribution of β (positively) and α~1~ receptors.
  [@B128]     MEG (humans)            DFA + computational model                             Atomoxetine (SNRI)                                    Rest: reduced α scaling exponent due to atomoxetine. Task (bistable perception): reduced α scaling exponent due to atomoxetine. Computational model accounted for the findings as a change in excitation relative to inhibition.
  [@B152]     fMRI (humans)           Seed-based correlation Graph theoretic analysis       Phenylalanine and tyrosine depletion (DA depletion)   Reduced correlations strength in sensorimotor, salience, and temporal networks. Reduced between-module correlation of the sensorimotor and salience networks.
  [@B129]     MEG (humans)            Graph theoretic analysis + computational model        Atomoxetine (SNRI)                                    Rest: no effect of atomoxetine. Task (bistable perception): Atomoxetine increased correlation strength. Computational models indicate that effects can be accounted for by an increase in gain.
  [@B191]     fMRI (mice)             Graph theoretic analysis (FCD) Dual regression        Chemogenetic LC stimulation                           Increase in global correlation strength. Increased correlation in the Salience, amygdala, auditory, striato-motor, and DMN networks.

ACC: anterior cingulate cortex; BG: basal ganglia; DA: dopamine; DFA: detrended fluctuation analysis; DMN: default mode network; vmPFC: ventromedial prefrontal cortex; LC: locus coeruleus; ll: left lateralized; MFG: middle frontal gyrus; IFG: Inferior frontal gyrus; vlPFC: ventrolateral prefrontal cortex; NE: norepinephrine; OFC: orbitofrontal cortex; SMG: supramarginal gyrus; PCC: posterior cingulate cortex; rl: right lateralized; FPN: frontoparietal network; SFG: superior frontal gyrus; SNRI: selective norepinephrine reuptake inhibitor.

###### 

Summary of main findings of (pharmacological) manipulation of 5HT and Ach.

  **Study**   **Modality(species)**       **Analysismethod**                                      **Manipulation**                                        **Main effects of manipulation on intrinsic correlations**
  ----------- --------------------------- ------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B165]     fMRI (humans)               ICA-based back-reconstruction                           Nicotine (nACh receptor agonist)                        Reduced correlations within the DMN. Increased correlations within extrastriate cortex.
  [@B108]     fMRI (humans)               Seed-based correlation                                  Citalopram (SSRI)                                       Citalopram: reduced amygdala-vmPFC correlation.
  [@B109]     fMRI (humans)               Seed-based correlation                                  Citalopram (SSRI)                                       Reduced correlation between left dmPFC and left hippocampus.
  [@B173]     fMRI (humans)               Dual regression                                         Escitalopram (SSRI)                                     Reduced DMN correlations with PCC, ACC, hippocampus, and lateral parietal cortex.
  [@B145]     fMRI (humans)               Graph theoretic analysis (FCD)                          Escitalopram (SSRI)                                     Reduced global strength of correlation. Local increases in thalamus and cerebellum.
  [@B89]      fMRI (humans)               Dual regression                                         Sertraline (SSRI)                                       Widespread decreases in correlation with DMN; executive control; visual and sensorimotor networks. Increased correlation between auditory network and PCC/precuneus.
  [@B28]      fMRI (humans)               Seed-based correlation                                  LSD (5HT agonist)                                       Increase in correlation between visual cortex and widespread regions of the cortex and between the parahippocampal cortex and the retrosplenial cortex and PCC, and increased correlations between parahippocampal cortex and dorsal mPFC and right dorsolateral PFC.
  [@B163]     fMRI (humans)               Graph theoretic analysis. Seed-based correlation        LSD (5HT agonist)                                       Increased global correlation strength. Brain regions that showed altered correlation strength overlapped with 5HT~2A~-r distributions. Increased correlation between four seeds (PFC, parietal cortex, precuneus, and thalamus) and sensorimotor areas. Reduced modularity. Increased participation coefficient of frontal and midline regions. Reduced rich-club coefficient.
  [@B88]      fMRI (humans)               Dual regression                                         Citalopram (SSRI) Galantamine (nACh receptor agonist)   Citalopram: reduction of correlations within the sensorimotor network, PFN, DMN, and executive control network. Galantamine: increased correlations between polar occipital network and distributed regions; between an auditory network and regions of the DMN and somatosensory cortex; reduced correlations within the DMN, and between DMN and lateral and inferior occipital cortices; between the FPN and DMN, inferior temporal and cerebellar regions.
  [@B45]      fMRI (humans)               Dynamic FC + computational model                        LSD (5HT agonist)                                       The model captured the effect of 5HT~2A~-r stimulation as an increase in gain to explain the effect of LSD on the distribution of FC dynamics.
  [@B170]     fMRI (rhesus macaque)       Global signal correlation and dual regression           Pharmacological inactivation of basal forebrain         Broad reductions in coupling of local activity with the global signal, corresponding spatially to the inactivated location. Topography of individual RSNs unaffected.
  [@B100]     fMRI (humans)               Dynamic FC                                              Psilocybin (5HT agonist)                                Longer dwell times for a global FC component. Reduced dwell times for FPN.
  [@B133]     fMRI (humans)               Graph theoretic analysis (FCD) Seed-based correlation   LSD (5HT agonist)                                       Reduced correlation (from positive toward zero) in associative networks. Increased correlation (from negative toward zero) in sensorimotor and thalamic networks. LSD effects correlated with 5HT~2A~-r distributions. Reduced correlation between sensorimotor areas and global signal.
  [@B128]     MEG (humans)                DFA + computational model                               Donepezil (acetylcholinesterase inhibitor)              No effect of donepezil.
  [@B129]     MEG (humans)                Graph theoretic analysis + computational model          Donepezil (acetylcholinesterase inhibitor)              Rest: reduced correlation strength. Computational models indicate that effect can be accounted for by an increase in gain.
  [@B66]      fMRI, MUA, and LFP (mice)   GLM analysis                                            Blockwise optogenetic stimulation of DR                 Wide suppression of cortical CBV response. Suppression of cortical MUA, and δ LFP power, which spatially correlated with the cortical CBV response. CBV response correlated with distribution of 5HT 1F, 2A, 2C receptors, but not 1A and 1B receptors. Correlations with receptor maps were stronger than correlation with DR projection profile.

5HT: serotonin; ACh: acetylcholine; ACC: anterior cingulate cortex; CBV: cerebral blood volume; DMN: default mode network; dmPFC: dorsomedial prefrontal cortex; DR: dorsal raphe; FC: functional connectivity; FPN: frontoparietal network; FCD: Functional connectivity density; PCC: posterior cingulate cortex; nACh: nicotinic acetylcholine; PCA: principle component analysis; SSRI: selective serotonin reuptake inhibitor.

Pharmacological elevations of the noradrenergic tone, while yielding a diversity of findings, have consistently produced effects that involve visual cortex. [@B38] reported an α~2~ agonist clonidine-induced reduction in effective connectivity to- and from posterior extrastriate visual cortex. Reduced correlations between early visual cortex and frontoparietal cortical areas have also been reported following the α~2~ agonist dexmedetomidine ([@B4]) and NET blocker atomoxetine ([@B176]). Similarly, [@B70] reported atomoxetine-induced reductions in correlation within a frontoparietal network and peripheral visual network. One study did not report changes in correlation of visual cortical areas following chemogenetic LC stimulation in rodents ([@B191]), potentially due to inter-species differences or differences between the effect of chemogenetic and pharmacological manipulation ([@B64]).

Manipulations of the cholinergic system have, likewise, yielded topographical effects that involve visual cortex. [@B165] reported a nicotine-induced increase in correlation strength within an extrastriate network, and [@B88] reported a galantamine (cholinesterase inhibitor) induced increase in correlation strength between a polar occipital network and widespread areas of the cortex. In addition, some, but not all ([@B70]), studies using noradrenergic or cholinergic agents have reported effects that involve the default mode network (DMN) ([@B165]; [@B4]; [@B176], [@B174]; [@B88]; [@B191]). The observation that noradrenergic or cholinergic agents consistently produced effects on intrinsic correlations in visual cortical areas could be due to the fact that NE receptors α~2A~ and β~1~, and ACh receptors NA~10~ and M~2~ are prominently expressed these regions ([Figure 2](#F2){ref-type="fig"}).

In contrast, primarily dopaminergic agents produced no effects on visual cortex, but instead on somatosensory and (pre-)motor cortex. For example, a positive relationship between DA levels and correlation strength between the basal ganglia and sensorimotor cortex ([@B36]), reduced correlation between the caudate and nodes of the sensorimotor network including pre- and postcentral gyri following D~2~ receptor agonism ([@B186]), and reduced correlation within the sensorimotor network following DA depletion ([@B152]). Dopaminergic effects in motor cortical regions may reflect direct modulations of dynamic state within the cortex, or down-stream effects of modulations of the efficacy of dopaminergic projections from the brainstem to the basal ganglia ([Figure 1](#F1){ref-type="fig"}).

Catecholaminergic manipulations have also been studied in the context of stress-related (re)activation patterns ([@B75]; [@B63]). These studies show prominent noradrenergic and dopaminergic effects on stress-induced changes in activation patterns or later reemergence thereof.

Studies using serotonergic agents have reported effects on intrinsic correlations resembling a combination of noradrenergic/cholinergic and dopaminergic effects: in other words, effects in both visual cortical and sensorimotor areas ([@B89], [@B88]; [@B28]; [@B163]; [@B133]). In particular, studies that used the 5HT~2A~ receptor agonist LSD consistently reported effects on visual cortex. Indeed, the 5HT~2A~ receptor is prominently expressed in visual cortex ([Figure 2](#F2){ref-type="fig"}).

Topologically Specific Changes of Intrinsic Correlation Strength {#S4.SS3}
----------------------------------------------------------------

Various analytical tools exist to characterize the topology of functional brain organization ([@B140]; [@B153]). For instance, the balance between topological segregation and integration of cortical ensembles is determined by the ratio of activity correlation strength within versus between separate modules ([@B107]; [@B156]), and has been related to behavioral performance ([@B153]). Topological variations in the segregation-integration balance of fMRI activity during rest covary with pupil diameter ([@B156]), a non-invasive proxy for activity in neuromodulatory nuclei ([@B120]; [@B178]; [@B84]; [@B23]). Thus, topological features of intrinsic activity correlations may be under neuromodulatory control.

Indeed, pharmacological upregulation of cortical NE levels using atomoxetine has been shown to result in a shift toward segregated processing during rest, and a converse shift toward integrated processing during the performance of a cognitively demanding (N-back) task ([@B155]). Similarly, [@B176] found that atomoxetine reduced between-module correlation strength, and reduced metrics of integration (clustering coefficient and transitivity) during rest. [@B69] reported reduced global efficiency, a metric of integration ([@B140]), but reduced clustering, due to atomoxetine in rhesus macaques.

Studies using DA manipulations seem to indicate that DA facilitates integration. [@B1] reported reduced metrics of global and local efficiency due to the D~2~ antagonist sulpride. [@B152] reported that DA depletion reduced the participation coefficient (between-module correlation) of the sensorimotor and salience networks. Thus, DA and NE may have dichotomous effects on network topology. However, null effects of DA agonism on various topological metrics, including metrics of integration, have also been reported ([@B186]). To the best of our knowledge, no studies to date have examined the effect of ACh manipulation on network topology, and one study has examined the effect of 5HT~2A~ agonism (via LSD) on fMRI intrinsic correlation topology ([@B163]). This study reported reduced modularity (increased integration), increased participation coefficient of frontal and midline regions (increased between-network correlation at the expense of within-network correlation), and reduced rich-club coefficient (less correlation with hub regions).

Summary and Outstanding Issues {#S4.SS4}
------------------------------

Pharmacological manipulation of tonic neuromodulatory action, and the resulting, putative change in cortical dynamic state, consistently alters the global strength of intrinsic correlations. Less consistent, however, is the direction of these effects, even *within* classes of neuromodulators. Further studies are needed to corroborate or exclude the following possible reasons for these discrepancies: cross-study differences in preprocessing such as global signal regression ([@B133]); dose-dependence of effects ([@B189]); or dependence of effects on cognitive/behavioral context ([@B38]; [@B155]; [@B129]) or baseline arousal ([@B182]).

Topographical effects following noradrenergic or cholinergic manipulation consistently involve visual cortex. Studies that used predominantly dopaminergic agents consistently report effects involving motor-related brain areas, but not visual brain areas. Studies that used a serotonergic agent report both visual and motor areas. This literature suggests that the regions that are most likely to be affected by pharmacological manipulation of neuromodulators are potentially distributed in accordance with the distribution of receptors across areas.

The predominant finding from studies on topological effects is that neuromodulators alter functional network topology, in particularly the catecholamines. These studies also suggest a possible distinction between the effects of DA and NE on network-level integration. Whereas NE reuptake during rest reduces topological metrics of integration, DA antagonism and depletion have the same effect, suggesting that DA facilitates integration. Similar to DA, 5HT seems to increase metrics of integration, but only one study has examined these effects. The influence of ACh on functional network topology remains to be studied.

A caveat with the findings on network topology is that some metrics of integration (in particular efficiency and clustering) are susceptible to changes in degree, even when artificially fixing degree of adjacency matrices by applying a fixed threshold ([@B177]). Since neuromodulators have been reported to alter degree as well (see section *changes of the global strength of intrinsic correlations*), future studies should carefully consider alterations in global degree when examining topological metrics. In addition, studies that have examined changes in the time-varying topology should take into account the influence of temporal fluctuations of the community structure on topological metrics ([@B167]).

Conclusion and Future Directions {#S5}
================================

Both (de)activation studies and seed-based correlation studies provide supporting evidence for ongoing fluctuations in the activity of neuromodulatory brainstem nuclei as a possible driving source of intrinsic activity correlations within the cortex. Temporary BF inactivation, NE release inhibition, DA synthesis inhibition, and rhythmic optogenetic serotonergic DR neuron stimulation all reduce intrinsic activity correlations. Furthermore, activity fluctuations in most neuromodulatory nuclei (BF; VTA; SN; LC) but not all (raphe nuclei) predict correlated activity fluctuations in broad areas of the cortex.

Pharmacological manipulation of cortical neuromodulator levels, which putatively alters cortical dynamic state, results in diverse changes of intrinsic activity correlations. First, pharmacological upregulation consistently changes the global strength of cortical correlations. Yet, in what direction the individual modulators exert their effects needs further study, since these effects are likely to be dependent on several factors, such as drug dose or behavioral context.

Second, several pharmacological studies have quantified neuromodulator-induced changes in the topography of cortical activity. Noradrenergic and cholinergic manipulation consistently alter activity correlations in visual cortical areas, dopaminergic manipulation affects motor cortical networks, and serotonergic manipulation affects both.

Finally, a number of studies have demonstrated that neuromodulators alter the topological properties of intrinsic activity correlations. These studies suggest a possible distinction between the effects of DA and NE on network-level functional integration. Similar to DA, 5HT seems to increase metrics of functional integration.

The studies discussed in this review may well have only scratched the surface the full spectrum of effects that neuromodulatory systems exert on intrinsic activity correlations. Even so, they open up exciting avenues for future work. An effort to map the contribution of each neuromodulatory system to the spatial and temporal features of intrinsic correlations may aid the identification of shared, independent, or antagonistic principles between the actions of different neuromodulatory systems and their diverse receptor classes. Such principles will inform models of healthy brain function and provide an important reference for the mechanistic understanding of neurological and psychiatric disorders. Ultimately, such principles may guide the way toward identification of specific molecular targets for mechanistically inspired and individualized pharmacological interventions in disorders of higher brain function. In what follows, we outline a number of important avenues for future research. Each of these could help advance our understanding of the principles that govern intrinsic brain dynamics and its dysfunctions in critical ways.

Dissecting the Mechanisms of Brainstem Modulation of Cortical Correlations {#S5.SS1}
--------------------------------------------------------------------------

We have highlighted that neuromodulatory brainstem systems may alter intrinsic correlations of cortical population activity through diverse mechanistic pathways. The fluctuating activity of brainstem nuclei may provide common drive to large swathes of cortical regions, or drive other subcortical regions (such as the pulvinar nucleus of the thalamus) that can in turn cause widespread changes in cortical activity ([@B124]; [@B6]). Second, neuromodulatory brainstem systems may also modulate the cortical dynamic state, thereby altering correlations in cortical population activity indirectly. These two mechanisms are non-mutually exclusive: the physiological effect of any neuromodulatory action likely results from a complex mixture of both. Nevertheless, careful experimental manipulations should tease these mechanisms apart and provide insight into the consequences of each mechanism for intrinsic activity fluctuations within the cortex.

For example, in order to test whether neuromodulatory systems induce temporal correlations in the cortex through common drive, one can manipulate the *time varying* activity of brainstem nuclei, and examine the time varying signature of this manipulation in cortical activity. Using optogenetics, specific neuron types can be targeted such that non-neuromodulatory (e.g., GABAergic) long-range projections that emanate from these nuclei are not directly affected by the experimental manipulation. Moreover, electrophysiological recordings within the cortex would circumvent interpretational caveats that are inherent to the transformation of neural activity into the fMRI signal ([@B99]). Experiments of this kind have shown promise ([@B66]). Combining such manipulations with the administration of pharmacological blockade of ionotropic receptors could ultimately provide decisive evidence in favor of or against the notion of drive of intrinsic activity correlations by neuromodulators.

Additionally, seed-based correlation studies can provide evidence of co-fluctuating activity in brainstem neuromodulatory nuclei and the cortex in humans. In order to elucidate the relationship between each neuromodulatory system and correlated activity within the cortex, studies are needed in which activity in all nuclei is measured simultaneously, and the covariation between the individual nuclei is taken into account. Such analyses have not yet been conducted, but can be readily implemented with existing techniques.

Another possible means to distinguishing multiple mechanisms of action is to examine the spatial correspondence between the effect of a manipulation of neuromodulators on cortical intrinsic activity correlations, and the distribution of specific receptors. These comparisons are now possible using open-access databases of genetic expression of receptor types ([@B73]), validated for use in neuroimaging ([@B68]). Such studies may benefit from analytical tools that are tailored to distil manipulation-related effects on cortical correlations in a specific direction, without relying on *a priori* selection of correlated networks (e.g., [@B174]). Examining the spatial relationship between the effect of a manipulation and the receptors may also be indicative of whether the cortical effect of a neuromodulator is determined primarily by the anatomical projection profile of the nucleus that releases it, or if the receptor distributions weigh more heavily ([@B66]). Moreover, such analyses should be used to contrast the impact of ionotropic and metabotropic receptors.

Developing Mechanistic Models and Biomarkers for Neuropsychiatric Disorders {#S5.SS2}
---------------------------------------------------------------------------

A detailed understanding of how neuromodulators shape intrinsic activity correlations may aid the development of novel biomarkers for neurological and psychiatric disorders, as well as mechanistic models of these disorders. Several disorders are associated with dysfunctions in one or multiple neuromodulatory brainstem systems. For example, Parkinson's disease is caused by degeneration of the dopaminergic midbrain nuclei, along with the noradrenergic LC. Cognitive decline in aging, in particular Alzheimer's disease, coincides with degeneration of the cholinergic BF and possibly the LC. Major depression and schizophrenia are associated with disturbances in catecholaminergic and serotonergic systems.

These clear associations with neuromodulatory brainstem systems are currently not exploited for the early detection and classification of such disorders. In particular, the current classification and diagnosis of psychiatric disorders is solely based on subjective assessments of behavioral symptoms, irrespective of the underlying pathophysiological mechanisms ([@B81]; [@B93]). One consequence of this coarse and phenomenological classification scheme is that patient populations in one diagnostic category are often heterogeneous in terms of the neural circuit deficits that give rise to the behavioral symptoms ([@B150]; [@B81]). This hampers the development of individualized treatment plans that target the key circuit disorder that underlies the cognitive or behavioral deficits of a given patient.

The insight that neuromodulators profoundly shape intrinsic activity correlations that are evident with non-invasive neuroimaging techniques opens the door for overcoming these limitations in current clinical practice. The insight sets the stage for the development of neural markers of psychiatric disorders that are directly grounded in the underlying pathomechanisms and cortical signatures of neuromodulatory action. Specifically, the changes in correlation patterns associated with (manipulations of) a specific neuromodulatory system can provide a "reference template" to which alterations of correlation patterns associated with specific disorders can be compared. Such markers may prove to reflect an individual patient's precise deficit more reliably and help identify molecular targets for pharmacological intervention.

In this light, it is important to evaluate the influence of behavioral context on the effect that neuromodulators exert on intrinsic activity correlations. Manipulation of neuromodulator levels has been shown to result in opposing effects on intrinsic activity correlations under different behavioral contexts ([@B38]; [@B155]; [@B129]). Direct comparisons of various neuromodulators within the same- and between different cognitive contexts can thus provide interpretational constraints on alterations of correlation patterns that are associated with psychiatric disorders. Moreover, such an approach may help resolve standing discrepancies in the literature regarding the direction of pharmacological effects on intrinsic activity correlations.

Lastly, neuromodulators interact, through reciprocal connections between the brainstem nuclei, shared cortical afferents, and cortical receptor co-expression. Because of this, dysfunction in a single neuromodulatory system is unlikely to occur without affecting others. Moreover, any neuromodulatory dysfunction that is associated with a psychiatric disorder may not be observable in intrinsic activity correlations as a linear summation of the above described reference templates of the individual neuromodulatory systems that are dysfunctional. Thus, further study on how the joint actions of neuromodulators shape cortical interactions is needed. A starting point is to incorporate receptor co-expression into large-scale computational models of cortical function, combined with coupling terms that link activity of one neuromodulatory system to that of another. This may capture interactions between these systems more accurately, and yield mechanistic insight about how dysfunction in these systems manifests itself at the level of intra-cortical processes and behavior.
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